Xenetic Biosciences, Inc. (XBIO)
| Market Cap | 6.62M |
| Revenue (ttm) | 2.52M |
| Net Income (ttm) | -4.08M |
| Shares Out | 1.54M |
| EPS (ttm) | -2.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,606 |
| Open | 4.170 |
| Previous Close | 4.100 |
| Day's Range | 4.160 - 4.309 |
| 52-Week Range | 2.780 - 5.200 |
| Beta | 2.24 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline in... [Read more]
Financial Performance
In 2023, Xenetic Biosciences's revenue was $2.54 million, an increase of 48.80% compared to the previous year's $1.71 million. Losses were -$4.13 million, -36.90% less than in 2022.
Financial StatementsNews
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of...
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc....
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / AC...
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company's rationale for incorporating DNas...
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications Ongoing progress towards first in human clinical study for...
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Data presented at Society for Immunotherapy of Cancer (SITC) 2024 Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against...
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc. (NASDAQ:X...
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology techn...
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic Bi...
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tec...
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Ongoing preclinical studies with data expected before year end Focus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indications Ended the quarter wit...
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of ...
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with...
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc...
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carci...
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Bioscience...
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tech...
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic s...
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Wednesday, July 12th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutic...
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
FRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors - Ended the quarter wit...
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.
Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise FRAMINGHAM, MA / ACCESSWIRE / May ...
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning FRAMINGHAM, MA / ACCESSWIRE / May 3, 2...
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development - Systemic DNase program initially targeting multi...
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Ph...